A relationship with no attachments

Zymeworks Inc. believes its Azymetric platform for creating bispecific antibodies is better than other technologies because it can create IgG1 antibodies without linkers or attachments in a pure, stable and scalable manner. Merck & Co. Inc. struck a deal with the biotech last month to develop products against undisclosed targets.

The partners potentially will be competing with at least two other companies developing heterodimeric, bispecific IgG1 antibodies without linkers or attachments: Amgen Inc. and the Genentech Inc. unit of Roche...